158 related articles for article (PubMed ID: 22408122)
1. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study.
Reynolds RM; Labad J; Sears AV; Williamson RM; Strachan MW; Deary IJ; Lowe GD; Price JF; Walker BR;
Eur J Endocrinol; 2012 May; 166(5):861-8. PubMed ID: 22408122
[TBL] [Abstract][Full Text] [Related]
2. Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug. A cross-sectional online survey of 820 patients.
Morin C; Fardet L
Clin Rheumatol; 2015 Dec; 34(12):2119-26. PubMed ID: 25956956
[TBL] [Abstract][Full Text] [Related]
3. Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial.
Chantzichristos D; Svensson PA; Garner T; Glad CA; Walker BR; Bergthorsdottir R; Ragnarsson O; Trimpou P; Stimson RH; Borresen SW; Feldt-Rasmussen U; Jansson PA; Skrtic S; Stevens A; Johannsson G
Elife; 2021 Apr; 10():. PubMed ID: 33821793
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid use and its association with skeletal health among U.S. adults with diabetes.
Casagrande SS; Cowie CC; Malozowski S
J Diabetes Complications; 2017 Feb; 31(2):353-357. PubMed ID: 27431890
[TBL] [Abstract][Full Text] [Related]
5. Glycemic control with a basal-bolus insulin protocol in hospitalized diabetic patients treated with glucocorticoids: a retrospective cohort study.
Chertok Shacham E; Kfir H; Schwartz N; Ishay A
BMC Endocr Disord; 2018 Oct; 18(1):75. PubMed ID: 30373567
[TBL] [Abstract][Full Text] [Related]
6. Association between use of systemic and inhaled glucocorticoids and changes in brain volume and white matter microstructure: a cross-sectional study using data from the UK Biobank.
van der Meulen M; Amaya JM; Dekkers OM; Meijer OC
BMJ Open; 2022 Aug; 12(8):e062446. PubMed ID: 36041764
[TBL] [Abstract][Full Text] [Related]
7. Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes.
Sommerfield AJ; Deary IJ; Frier BM
Diabetes Care; 2004 Oct; 27(10):2335-40. PubMed ID: 15451897
[TBL] [Abstract][Full Text] [Related]
8. The association between sociodemographic and clinical characteristics and poor glycaemic control: a longitudinal cohort study.
McBrien KA; Manns BJ; Hemmelgarn BR; Weaver R; Edwards AL; Ivers N; Rabi D; Lewanczuk R; Braun T; Naugler C; Campbell D; Saad N; Tonelli M
Diabet Med; 2016 Nov; 33(11):1499-1507. PubMed ID: 26526088
[TBL] [Abstract][Full Text] [Related]
9. Impact of socioeconomic status and gender on glycaemic control, cardiovascular risk factors and diabetes complications in type 1 and 2 diabetes: a population based analysis from a Scottish region.
Collier A; Ghosh S; Hair M; Waugh N
Diabetes Metab; 2015 Apr; 41(2):145-51. PubMed ID: 25454092
[TBL] [Abstract][Full Text] [Related]
10. Management of hyperglycaemia in persons with non-insulin-dependent type 2 diabetes mellitus who are started on systemic glucocorticoid therapy: a systematic review.
Tatalovic M; Lehmann R; Cheetham M; Nowak A; Battegay E; Rampini SK
BMJ Open; 2019 Jun; 9(5):e028914. PubMed ID: 31154314
[TBL] [Abstract][Full Text] [Related]
11. Distinct trajectories of HbA
Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
[TBL] [Abstract][Full Text] [Related]
12. Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study.
Reynolds RM; Strachan MW; Labad J; Lee AJ; Frier BM; Fowkes FG; Mitchell R; Seckl JR; Deary IJ; Walker BR; Price JF;
Diabetes Care; 2010 Apr; 33(4):714-20. PubMed ID: 20097784
[TBL] [Abstract][Full Text] [Related]
13. Leptin levels and depressive symptoms in people with type 2 diabetes: the edinburgh type 2 diabetes study.
Labad J; Price JF; Strachan MW; Fowkes FG; Deary IJ; Seckl JR; Walker BR; Sattar N; Reynolds RM;
Psychosom Med; 2012 Jan; 74(1):39-45. PubMed ID: 22210236
[TBL] [Abstract][Full Text] [Related]
14. [Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy].
Meyer G; Badenhoop K
Med Klin (Munich); 2003 Apr; 98(5):266-70. PubMed ID: 12721671
[TBL] [Abstract][Full Text] [Related]
15. Metabolic complications of glucocorticoids - Prevention by metformin.
Sanpawithayakul K; Korbonits M
Ann Endocrinol (Paris); 2023 Aug; 84(4):483-497. PubMed ID: 37209947
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis.
Wu J; Mackie SL; Pujades-Rodriguez M
BMJ Open Diabetes Res Care; 2020 Jul; 8(1):. PubMed ID: 32719077
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
19. Systemic and Local Corticosteroid Use Is Associated with Reduced Executive Cognition, and Mood and Anxiety Disorders.
Savas M; Vinkers CH; Rosmalen JGM; Hartman CA; Wester VL; van den Akker ELT; Iyer AM; McEwen BS; van Rossum EFC
Neuroendocrinology; 2020; 110(3-4):282-291. PubMed ID: 31220843
[TBL] [Abstract][Full Text] [Related]
20. Long-term systemic glucocorticoid therapy and weight gain: a population-based cohort study.
Fardet L; Nazareth I; Petersen I
Rheumatology (Oxford); 2021 Mar; 60(3):1502-1511. PubMed ID: 32864693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
